Current Pharmaceutical Design
Title:Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Volume: 22 Issue: 28
Author(s): Mohammad A. Kamal and Nigel H. Greig
Affiliation:
Export Options
About this article
Cite this article as:
Kamal A. Mohammad and Greig H. Nigel, Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C)), Current Pharmaceutical Design 2016; 22 (28) . https://dx.doi.org/10.2174/1381612822999160719150757
DOI https://dx.doi.org/10.2174/1381612822999160719150757 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Cardiovascular Imaging in Thromboembolic Risk Stratification for Atrial Fibrillation: Recent Patents and Current Practice
Recent Patents on Medical Imaging Animal Models of Systemic Sclerosis
Current Pharmaceutical Design Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Ghrelin: A Gastric Hormone with Cardiovascular Properties
Current Pharmaceutical Design The Pentacyclic Triterpenoids in Herbal Medicines and Their Pharmacological Activities in Diabetes and Diabetic Complications
Current Medicinal Chemistry Human Embryonic and Induced Pluripotent Stem Cell Based Toxicity Testing Models: Future Applications in New Drug Discovery
Current Medicinal Chemistry Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Murine Models of Vpr-Mediated Pathogenesis
Current HIV Research Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Antithrombotic Treatment in Cardiomyopathies
Current Pharmaceutical Design